Effect of Hydramitrazine (Lisidonil) in the Treatment of Neurogenic
Bladder Dysfunction EJNER PEDERSEN,** M.D.; VAGN GRYNDERUPt* B.M. Brit. med. J., 1966, 2, 271-273 Bladder dysfunction is a serious problem in many patients with neurological disorders. Such symptoms as frequency, urgency, and urge incontinence may compromise the patient's well-being and social adjustment. There is thus every reason to give energetic treatment to the neurogenic bladder. The experience gained in urological treatment of patients with traumatic paraplegia has to some extent been applied to other groups of patients, such as those suffering from multiple sclerosis or non-traumatic paraplegia. This actually marks a big step forward.
However, there is some divergence of opinion on the value of medical treatment of the neurogenic bladder, and several writers have expressed fairly pessimistic views. As a recent example may be cited McAlpine (1965) , who states that drugs may be given a trial, but that patients with a tendency to incontinence must be advised to use a urinal, which-as is well known-involves special problems for females.
In our opinion this pessimistic assessment of the value of medical treatment of the uninhibited neurogenic bladder is not justified. We shall try to demonstrate our reasons for this view by reporting our experience of seven years' work with the problems of bladder dysfunction. Lisidonil has occupied a central position in our programme of treatment. Comparison of Hydramitrazine and Banthine (Methanthelinium)
As a result of this confirmation of the pronounced effect of hydramitrazine on symptoms associated with the uninhibited neurogenic bladder it was decided to compare this drug with others in common use.
The treatment of the uninhibited neurogenic bladder with anticholinergic agents was introduced by Langworthy in 1936;  but the side-effects of atropine rendered effective long-term therapy difficult. Ephedrine has been used to some extent in spite of the fact that Lapides et al. (1958) reported that it was ineffective in the treatment of bladder and sphincteric dysfunction. The drugs most commonly used are quaternaryammonium derivatives, especially methanthelinium and propantheline bromide. The literature on methanthelinium, ,8-diethylamino-ethyl-xanthen-9-carboxylate methobromide, is the most exhaustive (Riskind and Zide, 1952; Keizur and Hodges, 1953; Lapides and Dodson, 1953a, 1953b; Lapides et al., 1958 ;  and others), and for this reason we decided to compare hydramitrazine with methanthelinium.
The comparison was made on 13 patients (seven women and six men) with multiple sclerosis or non-traumatic paraplegia. The patients were in a stationary phase without subjective or objective changes during the period of investigation; they had no urinary-tract infections; and both hydramitrazine and methanthelinium in the usual therapeutic doses were effective against the uninhibited bladder dysfunction of the patients.
After a preceding observation period without any treatment seven patients were treated first with hydramitrazine and then with methanthelinium, and six with methanthelinium first, followed by hydramitrazine. Hydramitrazine was given for an average period of 14 days in a daily dose of 11 mg./kg., and methanthelinium was given for nine days in a daily dose of 3.4 mg./kg. Cystometry was performed before and at the ends of the periods of treatment.
Clinically both drugs resulted in improvement of both subjective and objective symptoms, but there was a slight preponderance in favour of hydramitrazine. Some of the cysto-BRUTISH MEDICAL JOURNAL metrographic observations are given in Table I , and the amounts of residual urine are listed in Table II. It is seen that the treatment with methanthelinium resulted in significant changes-an increase in the volume of urine at the first desire to micturate, a reduction in the strength of the reflex contractions, and an increase in the amount of residual urine-whereas the treatment with hydramitrazine did not give a significant increase in residual urine. Further details are given by Pedersen and Grynderup (1966) .
Effect of Hydramitrazine in Routine Treatment
In order to analyse the effect of routine therapy we then reviewed a series of patients treated during the years 1961-2 at the Multiple Sclerosis Hospital, Ry. Of 238 patients admitted consecutively 137 had bladder dysfunction requiring treatment: 20 suffered exclusively from difficulty in voiding and the remaining 117 from frequent, urgent urination; of these 117 83 had urge incontinence.
Of the 117 patients with the complex of frequency and urgency 115 were given medical treatment comprising hydramitrazine, methanthelinium, atropine, and ephedrine. In the remaining two cases hydramitrazine was given a trial, but the treatment had to be discontinued because of nausea and dyspepsia.
In the total of 115 patients who were given medical treatment the symptoms were eliminated in 39, improvements were obtained in 48, while no effect was achieved in 28.
It is possible that in 32 of the patients therapy aiming at the elimination of urinary-tract infections would have been of importance for the improvement of the bladder dysfunction.
In 12 cases medical treatment with drugs other than hydramitrazine was given, or hydramitrazine was supplemented by other drugs.
Bladder Dysfunction-Pedersen and Grynderup BRITISH 273 When these two groups are excluded 71 patients remain in whom the effect must be ascribed to hydramitrazine (or spontaneous fluctuations in the condition). In the lastmentioned group the symptoms disappeared in 26, improvements were obtained in 32, whereas no effect was seen in 13. Increased difficulty in voiding or retention attributable to hydramitrazine did not occur. By 1965 hydramitrazine has been used in several hundred patients with excellent results, which it has been possible to maintain, except of course during severe progressions of the disease. We find that the drug is of great value and that it dramatically improves the situation in many cases ; in conditions which remain stationary the relief has been maintained for several years.
In routine treatment we give 10-11 mg. hydramitrazine per kg. body weight in 24 hours, administered in three oral doses, but a certain individual variation in dosage is advisable.
Side-effects
The side-effects of hydramitrazine therapy are slight, especially since the drug has become available in the form of coated tablets ; this had resulted in an almost complete disappearance of the earlier fairly frequent dyspeptic discomfort. 
Discussion
Experience gained over seven years has shown the value of hydramitrazine in the elimination of the symptoms of urgency, frequency, and urge incontinence associated with the uninhibited neurogenic bladder. This treatment has resulted in improvement in about 80% of the patients; in one-half of these the symptoms disappeared completely. The drug is used in many Scandinavian clinics with good results, though Blomberg and Kollberg (1961) reported that it was effective in only 11 out of 28 patients.
Hydramitrazine exerts its action without producing an increase in the residual urine, as occurs with anticholinergic agents. As emphasized by Miller et al. (1965) , anticholinergic agents should be used only when there is little or no residual urine. However, hydramitrazine may be given irrespective of the amounts of residual urine. If the effect of hydramitrazine is insufficient to relieve symptoms the result of treatment may, in cases with only small amounts of residual urine, be improved by combined therapy with anticholinergic drugs.
Hydramitrazine may exert its action on the detrusor muscle, but the influence on the cystometrogram seems to depend on the size of the dosage. On administration of large doses a shift to the right is a conspicuous feature in the cystometrogram. Kollberg and Peters6n (1963) injected intravenously an arbitrarily chosen dose of 150 mg. over a period of five minutes in 13 patients. Among eight of these patients, whom we find suitable subjects for a comparison (multiple sclerosis and traumatic paraplegia), cystometrographic changes in the threshold of reflex contraction occurred in three, with a shift to the right in two and a shift to the left in one. However, in cystometry the error in determination of the threshold of reflex contraction in the uninhibited neurogenic bladder is so great (Grynderup, 1966) that no definite conclusions can be drawn from these figures.
After intravenous injection of hydramitrazine in man electromyograms show a depression of the reflex activity-for example, of the H reflex (Pinelli, 1959) , stretch reflex, flexion reflex, and clonus (Struppler, 1960 )-and of the activity of the external urethral sphincter (Kollberg, Petersen, and Selld~n, 1962) . Even if there is no direct evidence that the effect obtained by intravenous injection of hydramitrazine can be reproduced by oral administration-theliteratureonmephenesin clearly demonstrates this-it is reasonable to assume that hydramitrazine exerts part of its action on the bladder symptoms through a depression of the activity of the external urethral sphincter. The depression of a spasticity of the external urethral sphincter might in part explain why hydramitrazine does not increase the residual urine.
In recapitulation it may be said that in our experience medical treatment of the neurogenic bladder is of great importance. If this therapy is supplemented by appropriate measures against urinary-tract infections and by surgical treatment-in particular, bladder-neck resection in an appreciable number of patients in whom this is indicated-it is possible to render considerable help, often of a permanent nature, to patients with neurological bladder disturbances. The use of an indwelling catheter should be a rare exception in patients with uninhibited neurogenic bladders, and the use of urinals need not be the rule. Summary Hydramitrazine, which is 2-hydrazino-4,6-bis-diethylamino-1,3,5-triazine-D-tartrate (Lisidonil), is a polysynaptic inhibitor which has proved to be very suitable in the treatment of the symptoms of frequency, urgency, and urge incontinence associated with the uninhibited neurogenic bladder.
Given in daily oral doses of 10-11 mg./kg. body weight, hydramitrazine results in improvement of the symptoms in about 80% of patients with multiple sclerosis, non-traumatic paraplegia, or other neurological disorders; in one-half of these the symptoms disappear completely.
As distinct from anticholinergic agents, hydramitrazine does not increase the amount of residual urine. It can therefore be used irrespective of the presence of residual urine. The sideeffects of the drug are slight.
Lisidonil was generously supplied by Ciba Ltd., Basle.
